Prenatal medication use in a prospective pregnancy cohort by pre-pregnancy obesity status.
Pre-pregnancy obesity
medication classes
medication use
pregnant women
prenatal medication
Journal
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
ISSN: 1476-4954
Titre abrégé: J Matern Fetal Neonatal Med
Pays: England
ID NLM: 101136916
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
pubmed:
13
3
2021
medline:
24
11
2022
entrez:
12
3
2021
Statut:
ppublish
Résumé
The association between obesity (body mass index (BMI) ≥ 30 kg/m To determine whether prenatal medication use, by the number and types of medications, varies by pre-pregnancy obesity status. In a secondary data analysis of a racially/ethnically diverse prospective cohort of pregnant women with low risk for fetal abnormalities enrolled in the first trimester of pregnancy and followed to delivery (singleton, 12 United States clinical sites), free text medication data were obtained at enrollment and up to five follow-up visits and abstracted from medical records at delivery. In 436 women with obesity and 1750 women without obesity (pre-pregnancy BMI, 19-29.9 kg/m Our findings suggest that pre-pregnancy obesity in otherwise healthy women is associated with a higher use of only selected medications (such as diabetes medications and progesterone) during pregnancy, while the intake of other more common medication types such as analgesics, antibiotics, and antacids does not vary by pre-pregnancy obesity status. As medication safety information for prenatal consumption is insufficient for many medications, these findings highlight the need for a more in-depth examination of factors associated with prenatal medication use.
Sections du résumé
BACKGROUND
UNASSIGNED
The association between obesity (body mass index (BMI) ≥ 30 kg/m
OBJECTIVES
UNASSIGNED
To determine whether prenatal medication use, by the number and types of medications, varies by pre-pregnancy obesity status.
METHODS
UNASSIGNED
In a secondary data analysis of a racially/ethnically diverse prospective cohort of pregnant women with low risk for fetal abnormalities enrolled in the first trimester of pregnancy and followed to delivery (singleton, 12 United States clinical sites), free text medication data were obtained at enrollment and up to five follow-up visits and abstracted from medical records at delivery.
RESULTS
UNASSIGNED
In 436 women with obesity and 1750 women without obesity (pre-pregnancy BMI, 19-29.9 kg/m
CONCLUSION
UNASSIGNED
Our findings suggest that pre-pregnancy obesity in otherwise healthy women is associated with a higher use of only selected medications (such as diabetes medications and progesterone) during pregnancy, while the intake of other more common medication types such as analgesics, antibiotics, and antacids does not vary by pre-pregnancy obesity status. As medication safety information for prenatal consumption is insufficient for many medications, these findings highlight the need for a more in-depth examination of factors associated with prenatal medication use.
Identifiants
pubmed: 33706661
doi: 10.1080/14767058.2021.1893296
pmc: PMC8802334
mid: NIHMS1760511
doi:
Substances chimiques
Progesterone
4G7DS2Q64Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5799-5806Subventions
Organisme : NICHD NIH HHS
ID : HHSN275201000009C
Pays : United States
Organisme : NICHD NIH HHS
ID : HHSN275200800014C
Pays : United States
Organisme : NICHD NIH HHS
ID : HHSN275200800028C
Pays : United States
Organisme : Intramural NIH HHS
ID : Z99 HD999999
Pays : United States
Organisme : NICHD NIH HHS
ID : HHSN275200800013C
Pays : United States
Organisme : NICHD NIH HHS
ID : HHSN275200800012C
Pays : United States